Pneumagen

Focus: Pneumagen is a newly founded (2024) UK-based biotech specializing in glycan-targeted carbohydrate binding modules for respiratory and infectious disease indications. The company operates as a public-stage entity with an early-stage pipeline.

Respiratory Infectious Diseases

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Pneumagen

AI assessmentNot Hiring

No open roles listed right now. Follow Pneumagen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Neumifil

Viral Respiratory Tract Infection

Phase 1

Clinical Trials (1)

NCT05093530Safety and Tolerability of Single and Multiple Doses of Neumifil

Phase 1

Help build intelligence for Pneumagen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a ground-floor opportunity at a 2024-founded biotech with novel glycan-targeting platform technology in high-unmet-need respiratory and infectious disease spaces
Participate in early pipeline development with Neumifil advancing through Phase 1/2 trials, offering exposure to drug discovery and clinical strategy from inception
Work in a UK-based hub (St. Andrews) with focused mission-driven science in emerging modalities

Watch Out For

Extreme early-stage risk: company founded in 2024 with only 2 active trials, no revenue, no approved products, and minimal public financial disclosure
Zero current hiring activity (0 open roles) and no employee count data suggests either stealth mode or resource constraints that may limit immediate career mobility
Pre-revenue biotech with unknown funding, cash runway, and burn rate creates significant employment stability uncertainty

Generated by Claude from Pneumagen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Neumifil

Influenza Viral Infections

Phase 2

Clinical Trials (1)

NCT05507567Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

Phase 2